Intelligene

Intelligene EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Intelligene (7832.TWO) as of Oct 20, 2026 is -53.91. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -378.06 — a change of -85.74% (higher).

EV/EBITDA

-53.91

YoY

-85.74%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Intelligene is 2024 -53.91 . EV/EBITDA (Enterprise Value to EBITDA) of Intelligene was 2023 -378.06 . It decreases by -85.74% higher compared to the previous year.

The Intelligene EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2023
-378.06 TWD
Jan 1, 2024
-53.91 TWD
The Intelligene EV/EBITDA history
YEAREV/EBITDAYoY
-53.91-85.74%
-378.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligene Stock analysis

What does Intelligene do? Intelligene Inc develops innovative RNA gene therapy drugs using siRNA gene compilation technology for treating pneumonia and influenza. The company focuses on research and development of nucleic acid drugs targeting all cases of pneumonia and influenza. Intelligene Inc is a Taiwan-based company with 20 full-time employees operating in the pharmaceutical industry. The company's primary revenue comes from the development and potential commercialization of its RNA-based gene therapy drugs. Intelligene Inc is engaged in the research and development of innovative nucleic acid drugs based on siRNA technology for pneumonia and influenza treatments. The firm aims to provide novel therapeutic solutions for respiratory diseases through its proprietary technology. Intelligene Inc's products target medical professionals and healthcare institutions seeking advanced treatments for pneumonia and influenza. The company's research focuses on developing drugs that address all cases of these respiratory conditions. The firm operates within the pharmaceutical sector with a specific emphasis on RNA-based therapies for respiratory illnesses. Intelligene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligene stock

EV/EBITDA (Enterprise Value to EBITDA) of Intelligene is -53.91 in 2024.

EV/EBITDA (Enterprise Value to EBITDA) of Intelligene changed from -378.06 to -53.91, representing a -85.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Intelligene since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Intelligene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Intelligene

All Key Metrics — Intelligene